Clinical Trial Update: Effects of PINTA 745 in End Stage Renal Disease (ESRD) Patients Who Require Hemodialysis and Have Protein Energy Wasting [Phase 1, Phase 2]

View source ↗

Summary

A ClinicalTrials.gov update notes the completion of Phase 1 and Phase 2 trials evaluating PINTA 745 in adults with end-stage renal disease on hemodialysis and p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• End-stage Renal Disease
• Protein-energy Wasting

Drugs mentioned

• PINTA 745 (PINTA-745)

Snippet

Sponsor: Pinta Biotherapeutics | Conditions: End Stage Renal Disease, Kidney Disease | Phase 1, Phase 2 | Status: COMPLETED